person · Reporting owner

HUFF CURTIS W

Disclosed activity across 3 companies

Tapewire entity: 70461
SEC CIK: 0001250127

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Comera Life Sciences Holdings, Inc.CMRA · Entity 94670	10% owner	December 29, 2023	January 03, 2024
Ernexa Therapeutics Inc.ERNA · Entity 8278	10% owner	December 14, 2023	December 19, 2023
PATTERSON UTI ENERGY INCPTEN · Entity 2270	Director	January 01, 2026	January 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Comera Life Sciences Holdings, Inc.

Report date December 29, 2023 · Filed January 03, 2024

Jointly reported with Freebird Partners LP, Freebird Investments LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Convertible Note SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2024-12-29	Direct	2,453,636	Reported balance After 2023-12-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-12-29 · Purchase · Acquired 2,453,636 · Balance 2,453,636 F1: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F2: Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). F3: (Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company.
Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.06 · Expires 2028-12-29	Direct	7,362,005	Reported balance After 2023-12-29 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-29 · Purchase · Acquired 4,907,272 · Balance 7,362,005 F2: Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). F3: (Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. F1: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

Filing footnotes · ownership attribution and instrument terms

F1: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F2: Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions").

F3: (Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company.

Ernexa Therapeutics Inc.

Report date December 14, 2023 · Filed December 19, 2023

Jointly reported with Freebird Partners LP, Freebird Investments LLC

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2028-06-02	Direct	524,474	Reported balance After 2023-12-14 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-12-14 · Disposition to issuer · Acquired 424,928 · Balance 524,474 F1: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.
Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2028-06-02	Direct	949,402	Reported balance After 2023-12-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-12-14 · Grant · Acquired 424,928 · Balance 949,402 F1: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.
Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2028-07-14	Direct	424,928	Reported balance After 2023-12-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-12-14 · Disposition to issuer · Acquired 524,474 · Balance 424,928 F1: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.
Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2028-07-14	Direct	949,402	Reported balance After 2023-12-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-12-14 · Grant · Acquired 524,474 · Balance 949,402 F1: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.
Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.43 · Expires 2028-12-15	Direct	1,991,394	Reported balance After 2023-12-15 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-12-15 · Purchase · Acquired 1,041,992 · Balance 1,991,394 F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.
Convertible Note SharesSEC Table II · derivative / convertible security · Conversion / exercise price $1.92 · Expires 2028-12-15	Direct	783,233	Reported balance After 2023-12-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-12-15 · Purchase · Acquired 520,996 · Balance 783,233 F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

Filing footnotes · ownership attribution and instrument terms

F1: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price.

F2: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners.

F3: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised

F4: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company.

PATTERSON UTI ENERGY INC

Report date January 01, 2026 · Filed January 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	450,040	Reported balance After 2026-01-01 transaction · row 1 1 source row Row 1 · 2026-01-01 · Grant · Acquired 40,098 · Balance 450,040 F1: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2027.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 01, 2026 Filed Jan 6, 2026 01:05 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock	40,098	$0.00	$0.00	Disclosure SEC source: 0001250127-26-000002 · wk-form4_1767661550.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 450,040 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2027. Read SEC document
January 01, 2025 Filed Jan 3, 2025 22:12 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	29,661	$0.00	$0.00	Disclosure SEC source: 0000889900-25-000003 · wk-form4_1735942313.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,942 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2026. Read SEC document
January 01, 2024 Filed Jan 4, 2024 00:52 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	22,685	$0.00	$0.00	Disclosure SEC source: 0001209191-24-000566 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 380,281 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2025. Read SEC document
December 29, 2023 Filed Jan 3, 2024 20:09 UTC	Comera Life Sciences Holdings, Inc. CMRA · Entity 94670	PurchaseCommon Stock Purchase Warrant · Derivative	4,907,272	Not disclosed Strike: $0.06	Not disclosed	Disclosure SEC source: 0000950170-24-001385 · ownership.xml · derivative · entry 2 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,362,005 Underlying: Common Stock, par value $0.0001 per share · 4,907,272 shares Expires 2028-12-29 F2 · price: Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). F3 · price: (Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. F1 · ownership.direct: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F2 · ownership.direct: Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). F3 · ownership.direct: (Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 29, 2023 Filed Jan 3, 2024 20:09 UTC	Comera Life Sciences Holdings, Inc. CMRA · Entity 94670	PurchaseConvertible Note Shares · Derivative	2,453,636	$0.06 Strike: $0.06	$134,949.98	Disclosure SEC source: 0000950170-24-001385 · ownership.xml · derivative · entry 1 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,453,636 Underlying: Common Stock, par value $0.0001 per share · 2,453,636 shares Expires 2024-12-29 F1 · ownership.direct: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.0001 ("Common Stock") of Comera Life Sciences Holdings, Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F2 · ownership.direct: Pursuant to that certain Securities Purchase Agreement dated December 29, 2023, as announced in the Issuer's Current Report on Form 8-K filed with the Securities Exchange Commission on December 29, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $134,950, (i) a Senior Convertible Note in the principal amount of $134,950 (the "Note") with a one (1) year term, and (ii) a warrant to purchase up to 4,907,272 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). F3 · ownership.direct: (Continued from footnote 2) The Note may be converted at any time and from time to time after December 29, 2023, at the option of the holder, at a conversion price of $0.055 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 29, 2023, and may be exercised through December 29, 2028, at an exercise price of $0.055 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own no more than 9.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 15, 2023 Filed Dec 19, 2023 02:38 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	PurchaseCommon Stock Purchase Warrant · Derivative	1,041,992	Not disclosed Strike: $1.43	Not disclosed	Disclosure SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 6 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,991,394 Underlying: Common Stock, par value $0.005 per share · 1,041,992 shares Expires 2028-12-15 F3 · price: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · price: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 15, 2023 Filed Dec 19, 2023 02:38 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	PurchaseConvertible Note Shares · Derivative	520,996	$1.92 Strike: $1.92	$999,999.72	Disclosure SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 5 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 783,233 Underlying: Common Stock, par value $0.005 per share · 520,996 shares Expires 2028-12-15 F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 14, 2023 Filed Dec 19, 2023 02:38 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	GrantCommon Stock Purchase Warrant · Derivative	524,474	Not disclosed Strike: $1.43	Not disclosed	Disclosure SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 4 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,402 Underlying: Common Stock, par value $0.005 per share · 524,474 shares Expires 2028-07-14 F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 14, 2023 Filed Dec 19, 2023 02:38 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	Disposition to issuerCommon Stock Purchase Warrant · Derivative	524,474	Not disclosed Strike: $2.61	Not disclosed	Disclosure SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 3 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 424,928 Underlying: Common Stock, par value $0.005 per share · 524,474 shares Expires 2028-07-14 F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 14, 2023 Filed Dec 19, 2023 02:38 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	GrantCommon Stock Purchase Warrant · Derivative	424,928	Not disclosed Strike: $1.43	Not disclosed	Disclosure SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 2 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,402 Underlying: Common Stock, par value $0.005 per share · 424,928 shares Expires 2028-06-02 F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. Read SEC document
December 14, 2023 Filed Dec 19, 2023 02:38 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	Disposition to issuerCommon Stock Purchase Warrant · Derivative	424,928	Not disclosed Strike: $3.28	Not disclosed	Disclosure SEC source: 0000950170-23-071263 · ownership.xml · derivative · entry 1 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 524,474 Underlying: Common Stock, par value $0.005 per share · 424,928 shares Expires 2028-06-02 F1 · kind: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F1 · price: On December 14, 2023, Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which the Eterna Therapeutics Inc. (the "Company") amended all outstanding warrants issued to the Reporting Persons (as defined below) on each of December 2, 2022, and July 13, 2023, such that the exercise price was lowered to $1.43 per share. The reduction in exercise price is reflected on this Form 4 as cancellation of the old derivative security and a re-grant of the new derivative security at the new exercise price. F2 · ownership.direct: This report is filed jointly by Freebird Partners, Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of the Company. These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F3 · ownership.direct: Pursuant to the Agreement, on December 14, 2023, Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $1,000,000, (i) a Senior Convertible Note in the principal amount of $1,000,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 1,041,992 shares of Common Stock (the "Warrant" and such transactions the "Transactions"). The Transactions closed on December 15, 2023. The Note may be converted at any time and from time to time after December 15, 2023, at the option of the holder, at a conversion price of $1.9194 per share of Common Stock, to the extent that after giving effect to such conversion the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of Securities Exchange Act of 1934, as amended (the "Exchange Act"), no more than 19.99% of the outstanding shares of Common Stock of the Company. The Warrant became exercisable on December 15, 2023, and may be exercised F4 · ownership.direct: (Continued from footnote 3) through December 15, 2028, at an exercise price of $1.43 per share of Common Stock, to the extent that after giving effect to such exercise the Reporting Persons and their affiliates would beneficially own, for purposes of Section 13(d) of the Exchange Act, no more than 19.99% of the outstanding shares of Common Stock of the Company. Read SEC document
July 14, 2023 Filed Jul 18, 2023 10:10 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	PurchaseCommon Stock Purchase Warrant · Derivative	524,474	Not disclosed Strike: $2.61	Not disclosed	Disclosure SEC source: 0000899243-23-017414 · doc4.xml · derivative · entry 2 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,402 Underlying: Common Stock, par value $0.005 per share · 524,474 shares Expires 2028-07-14 F2 · price: On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock. F1 · ownership.direct: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F2 · ownership.direct: On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock. Read SEC document
July 14, 2023 Filed Jul 18, 2023 10:10 UTC	Ernexa Therapeutics Inc. ERNA · Entity 8278	PurchaseConvertible Note Shares · Derivative	262,237	$2.86 Strike: $2.86	$749,997.82	Disclosure SEC source: 0000899243-23-017414 · doc4.xml · derivative · entry 1 Freebird Partners LP · CIK 0001955231 · 10% owner Freebird Investments LLC · CIK 0001971406 · 10% owner HUFF CURTIS W · CIK 0001250127 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,237 Underlying: Common Stock, par value $0.005 per share · 262,237 shares Expires 2028-07-14 F1 · ownership.direct: This report is filed jointly by Freebird Partners LP, a Texas limited partnership ("Freebird Partners"), Freebird Investments LLC, a Texas limited liability company ("Freebird Investments"), and Curtis W. Huff (each a "Reporting Person" and collectively, the "Reporting Persons") in connection with their respective direct and indirect ownership of common stock, par value $0.005 ("Common Stock") of Eterna Therapeutics Inc. (the "Company"). These securities of the Company are held of record by Freebird Partners. Freebird Investments serves as the general partner of Freebird Partners. Curtis W. Huff is the sole member of Freebird Investments. By virtue of these relationships, each of Freebird Investments and Mr. Huff may be deemed to share beneficial ownership of the securities held of record by Freebird Partners. F2 · ownership.direct: On July 13, 2023, Freebird Partners entered into that certain Securities Purchase Agreement (the "Agreement"), pursuant to which Freebird Partners agreed to purchase, and the Company agreed to sell, for an aggregate purchase price of $750,000, (i) a Senior Convertible Note in the principal amount of $750,000 (the "Note") with a five (5) year term, and (ii) a warrant to purchase up to 524,474 shares of Common Stock (the "Warrant" and such transactions the "Transactions". The Transactions closed on July 14, 2023. The Note may be converted at any time and from time to time after July 14, 2023, at the option of the holder, at a conversion price of $2.86 per share of Common Stock. The Warrant becomes exercisable on July 14, 2023, and may be exercised through July 14, 2028, at an exercise price of $2.61 per share of Common Stock. Read SEC document
January 01, 2023 Filed Jan 4, 2023 21:45 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	13,361	$0.00	$0.00	Disclosure SEC source: 0001209191-23-000997 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,596 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2024. Read SEC document
January 01, 2022 Filed Jan 3, 2022 21:21 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	26,627	$0.00	$0.00	Disclosure SEC source: 0001209191-22-000159 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,235 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2023. Read SEC document
January 01, 2021 Filed Jan 4, 2021 22:18 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	28,125	$0.00	$0.00	Disclosure SEC source: 0001209191-21-000389 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,608 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2022. Read SEC document
March 11, 2020 Filed Mar 12, 2020 20:20 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	PurchaseCommon Stock, $.01 par value per share	70,000	$2.06	$144,088.00	Disclosure SEC source: 0001209191-20-018494 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,483 F1 · price: Weighted average price. Actual purchase prices ranged from $2.0000 to $2.0900. Read SEC document
March 09, 2020 Filed Mar 10, 2020 20:02 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	PurchaseCommon Stock, $.01 par value per share	40,000	$2.36	$94,400.00	Disclosure SEC source: 0001209191-20-017632 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,483 F1 · price: Weighted average price. Actual purchase prices ranged from $2.355 to $2.360. Read SEC document
January 01, 2020 Filed Jan 3, 2020 21:07 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	16,666	$0.00	$0.00	Disclosure SEC source: 0001209191-20-000789 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,483 F1 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2021. Read SEC document
August 23, 2019 Filed Aug 24, 2019 01:25 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	PurchaseCommon Stock, $.01 par value per share	25,000	$8.08	$202,075.00	Disclosure SEC source: 0001209191-19-047390 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,817 Read SEC document
January 01, 2019 Filed Jan 3, 2019 22:21 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionRestricted Stock Units · Derivative	7,605	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-001172 · doc4.xml · derivative · entry 3 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 par value per share · 7,605 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One hundred percent (100%) of the restricted stock units vested on January 1, 2019. F3 · derivative.expiration_date: One hundred percent (100%) of the restricted stock units vested on January 1, 2019. Read SEC document
January 01, 2019 Filed Jan 3, 2019 22:21 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	16,908	$0.00	$0.00	Disclosure SEC source: 0001209191-19-001172 · doc4.xml · nonDerivative · entry 2 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,817 F2 · shares: Restricted stock units that convert into common stock on a one-for-one basis. One hundred percent (100%) of the restricted stock units vests on January 1, 2020. Read SEC document
January 01, 2019 Filed Jan 3, 2019 22:21 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionCommon Stock, $.01 par value per share	7,605	$0.00	$0.00	Disclosure SEC source: 0001209191-19-001172 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired upon the conversion of restricted stock units into common stock. Read SEC document
December 26, 2018 Filed Dec 27, 2018 21:13 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	PurchaseCommon Stock, $.01 par value per share	20,000	$10.14	$202,800.00	Disclosure SEC source: 0001209191-18-064174 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,304 F1 · price: Weighted average price. Actual purchase prices ranged from $10.139 to $10.14. Read SEC document
January 01, 2018 Filed Jan 3, 2018 21:17 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantRestricted Stock Units · Derivative	7,605	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-18-000852 · doc4.xml · derivative · entry 2 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,605 Underlying: Common Stock, $.01 par value per share · 7,605 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: One hundred percent (100%) of the restricted stock units vests on January 1, 2019. F2 · derivative.expiration_date: One hundred percent (100%) of the restricted stock units vests on January 1, 2019. Read SEC document
December 01, 2017 Filed Dec 4, 2017 21:10 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $19.52	$0.00	Disclosure SEC source: 0001209191-17-063511 · doc4.xml · derivative · entry 3 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 par value per share · 10,000 shares Expires 2017-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 01, 2017 Filed Dec 4, 2017 21:10 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Tax withholdingCommon Stock, $.01 par value per share	8,880	$21.98	$195,182.40	Disclosure SEC source: 0001209191-17-063511 · doc4.xml · nonDerivative · entry 2 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,304 F2 · shares: Shares disposed to pay exercise price of option. Read SEC document
December 01, 2017 Filed Dec 4, 2017 21:10 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionCommon Stock, $.01 par value per share	10,000	$19.52	$195,200.00	Disclosure SEC source: 0001209191-17-063511 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired upon exercise of option. Read SEC document
January 01, 2017 Filed Jan 4, 2017 21:07 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	GrantCommon Stock, $.01 par value per share	6,500	$0.00	$0.00	Disclosure SEC source: 0001209191-17-000813 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,184 F1 · shares: One hundred percent (100%) of the shares vest on January 1, 2018. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $15.35	$0.00	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · derivative · entry 7 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 par value per share · 10,000 shares Expires 2019-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · derivative · entry 6 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 par value per share · 10,000 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $21.95	$0.00	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · derivative · entry 5 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 par value per share · 10,000 shares Expires 2017-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionCommon Stock, $.01 par value per share	10,000	$15.35	$153,500.00	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · nonDerivative · entry 4 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired upon exercise of option. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionCommon Stock, $.01 par value per share	10,000	$11.51	$115,100.00	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · nonDerivative · entry 3 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,684 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired upon exercise of option. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Tax withholdingCommon Stock, $.01 par value per share	8,196	$26.78	$219,488.88	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · nonDerivative · entry 2 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,684 F2 · shares: Shares disposed to pay exercise price of option. Read SEC document
December 16, 2016 Filed Dec 20, 2016 21:49 UTC	PATTERSON UTI ENERGY INC PTEN · Entity 2270	Exercise / conversionCommon Stock, $.01 par value per share	10,000	$21.95	$219,500.00	Disclosure SEC source: 0001209191-16-156128 · doc4.xml · nonDerivative · entry 1 HUFF CURTIS W · CIK 0001250127 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Acquired upon exercise of option. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.